Advanced Therapy Medicinal Products (ATMPs)

With European life sciences R&D investment at a 20-year low, biopharmaceutical associations and MEPs are calling on the EU to modernise its policies. DDW’s Diana Spencer asks what will be needed for Europe to compete in the growing global market for advanced therapies.  A new report by Charles River Associates for the European Federation of […]

Where globally is innovation occurring and what factors – industry, regulatory, and academia – are helping developers get their products to market? Here, DDW Editor Reece Armstrong explores the global hubs of innovation for cell and gene therapies. Since the approval of Kymirah in 2017, the cell and gene therapy sector has emerged as an […]

Recent OBE recipient and SLAS Europe 2022 keynote speaker Steve Rees tells DDW’s Megan Thomas his thoughts on the themes of SLAS Europe 2022, the value of returning to face-to-face meetings, the influence the organisation has on his work and the industry’s key changes since the SLAS was formed in 2010. SLAS Europe 2022 themes […]

The UK has been highlighted as a leader in clinical trials for Advanced Therapy Medicinal Products (ATMPs), after a report published by the Cell and Gene Therapy Catapult (CGT Catapult) displayed the sector’s continued growth in the UK. The report CGT Catapult’s 2021 Advanced Therapy Medicinal Product (ATMP) report shows that there were 168 ATMP […]